OncoMate MSI Dx Analysis System
Promega Corporation · Decision date Nov 5, 2025
What did the FDA approve?
FDA records P240026 as an original PMA application. The recorded decision is approval, dated Nov 5, 2025.
FDA approval order statement
Approval for the OncoMate MSI Dx Analysis System. The OncoMate MSI Dx Analysis System is a qualitative multiplex polymerase chain reaction (PCR) test intended to detect the deletion of mononucleotides in five microsatellite loci (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) for the identification of microsatellite instability (MSI) using DNA obtained from formalin-fixed, paraffin-embedded (FFPE) endometrial carcinoma tissue specimens, and DNA isolated from matched normal FFPE specimen or whole blood. The OncoMate MSI Dx Analysis System is for use with the Applied Biosystems 3500 Dx Genetic Analyzer and OncoMate MSI Dx Analysis Software.The OncoMate MSI Dx Analysis System is indicated for use as a companion diagnostic test to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA (pembrolizumab) in combination with LENVIMA (lenvatinib) in accordance with the approved therapeutic product labeling.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Nov 5, 2025
Regulatory record facts
- Identifier
- P240026
- Regulatory pathway
- Premarket approval application
- Applicant
- Promega Corporation
- Product code
- SFL
- Decision code
- APPR
- Decision date
- Nov 5, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Nucleic Acid Based Assay, Microsatellite Instability.
- Applicant
- Promega Corporation
- Product code
- SFL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240026 received
Application receipt date recorded by FDA.
P240026 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P240026. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code SFL
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Promega Corporation | PMA approval | Sep 15, 2026 | FDA | |
Idylla CDx MSI TestP250005 | Biocartis Us, Inc. | PMA approval | Aug 15, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Promega Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2800 Woods Hollow Rd., Madison, WI, 53711
Sources and methodology
- Original FDA record: P240026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
